Sejal Glass Delivers 3x Net Profit Growth in FY25

Mumbai (Maharashtra) [India], May 10: Sejal Glass Limited (NSE: SEJALLTD, BSE: 532993), one of the leading architectural glass manufacturers announced Audited Q4 and FY25 Financial Results.

Q4 FY25 Consolidated Financial Highlights

Total Income of ₹ 67.90 Cr, YoY growth of 35.19%
EBITDA of ₹ 9.84 Cr, YoY growth of 68.31%
EBITDA Margin (%) of 14.49%, YoY growth of 285 BPS
Net Profit of ₹ 3.78 Cr, YoY growth of 1,080.86%
Net Profit Margin (%) of 5.57%, YoY growth of 493 BPS
EPS of ₹ 3.75, YoY growth of 1,109.68%

Q4 FY25 Standalone Financial Highlights

Total Income of ₹ 21.86 Cr, YoY growth of 20.99%
EBITDA of ₹ 6.27 Cr, YoY growth of 227.64%
EBITDA Margin (%) of 28.69%, YoY growth of 1,809 BPS
Net Profit of ₹ 4.17 Cr, YoY growth of 3,944.38%
Net Profit Margin (%) of 19.10%, YoY growth of 1,853 Bps
EPS of ₹ 4.13, YoY growth of 4,030.00%

FY25 Consolidated Financial Highlights

Total Income of ₹ 244.95 Cr, YoY growth of 48.70%
EBITDA of ₹ 35.34 Cr, YoY growth of 65.85%
EBITDA Margin (%) of 14.43%, YoY growth of 149 BPS
Net Profit of ₹ 11.03 Cr, YoY growth of 230.93%
Net Profit Margin (%) of 4.50%, YoY growth of 248 BPS
EPS of ₹ 10.85, YoY growth of 231.80%

FY25 Standalone Financial Highlights

Total Income of ₹ 70.56 Cr, YoY growth of 15.68%
EBITDA of ₹ 12.22 Cr, YoY growth of 73.64%
EBITDA Margin (%) of 17.32%, YoY growth of 578 BPS
Net Profit of ₹ 4.00 Cr, YoY growth of 688.76%
Net Profit Margin (%) of 5.67%, YoY growth of 484 BPS
EPS of ₹ 3.96, YoY growth of 629.00%

Operational Highlights 

  • In FY25, international revenue contributed 74.13% and domestic revenue 25.87% to the total revenue.
  • International revenue grew by 73.16% compared to FY24

Commenting on the performance, Mr. Amrut Gada, Promoter of Sejal Glass Limited said, ” FY25 has been an exceptional year for Sejal Glass, marked by a threefold growth in consolidated net profit—an outcome of sound strategy, operational discipline, and a sharp market focus. After coming out of the NCLT process, our focus has been on strengthening operations, expanding our market presence, and regaining the trust of all stakeholders. I’m proud of the progress we’ve made in improving capacity utilization, launching value-added products, and tapping into high-potential international markets, particularly in the Middle East.

We remain deeply committed to innovation and customer-centricity. Our upcoming bulletproof glass product is just one example of how we’re evolving to meet the demands of tomorrow. With a strong pipeline of projects and recent strategic acquisition of “Glasstech” Business in India by adding two more manufacturing plants in India, I believe we are well on track to achieving our long-term vision of becoming a global force in architectural and high-performance glass industry.”

If you have any objection to this press release content, kindly contact [email protected] to notify us. We will respond and rectify the situation in the next 24 hours.

aayush jain acquisition Business cashew processing cote d’ivoire esos 2026 pacific global fzco Pajson Agro pulkit jain Royal Mewa Share Swap

From Local to Global: Pajson Agro India to Acquire Pacific Global FZCO, Adding 60,000 MT Capacity at the World’s Largest Cashew Origin

All-stock 100% acquisition | ₹354.52 crore | Board also approves ESOS 2026 New Delhi [India], November 6: Pajson Agro India Limited (PAJSON | 544657 | INE14LM01012), a vertically integrated cashew processing company with farm-gate sourcing across key producing origins and a growing consumer brand, ‘Royal Mewa’, has announced that its Board of Directors, has approved […]

Read More
Business Fredun Pharmaceuticals EBITDA Growth Fredun Pharmaceuticals H1 FY27 Results Fredun Pharmaceuticals Net Profit Fredun Pharmaceuticals Revenue Growth Indian pharmaceutical industry

Fredun Pharmaceuticals On A Growth Overdrive: Net Profit Soars 94%, Ebitda Rockets 92% And Revenue Surges 87% In H1 Fy27

Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights […]

Read More
Business

Patil Automation Marks a Strong First Half of FY27; Consolidated Revenue Up 37% YoY, Net Profit Up 48%

Mumbai (Maharashtra) [India], November 6: Patil Automation Limited (NSE: PATILAUTOM | INE17GV01016), a leading provider of turnkey welding, assembly and robotics-integrated automation solutions, has released its Unaudited Standalone and Consolidated Financial Results for the half year ended September 30, 2026, reporting broad-based growth across the group. Performance Snapshot – H1 FY27 H1 FY27 Key Financial […]

Read More